TGF Beta antibody | TB21

100% Secure

Mouse anti Human TGF Beta

Product Type
Monoclonal Antibody
Product Code Applications Pack Size List Price Quantity
C E F* P* WB
0.1 mg loader

C F* P
10 µg loader

Mouse anti Human TGF beta antibody, clone TB21 recognizes both human platelet-derived and recombinant TGF-beta1 in enzyme-linked immunosorbent assay (ELISA). Mouse anti Human TGF beta antibody, clone TB21 demonstrates neutralising activity against TGF-beta1 in cell proliferation assays. Mouse anti Human TGF beta antibody, clone TB21 has been demonstrated to react with dimeric (~25 kDa) or monomeric (~12.5 kDa) molecules of natural TGF-beta1 under non-reducing and reducing conditions respectively.

Product Details

Target Species
Species Cross-Reactivity
Target SpeciesCross Reactivity
N.B. Antibody reactivity and working conditions may vary between species.
Product Form
Purified IgG - liquid
Purified IgG prepared by affinity chromatography
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
<0.1% Sodium Azide (NaN3)
Human Transforming Growth Factor Beta 1 from platelets.
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml
Fusion Partners
Spleen cells from immunised Balb/c mice were fused with cells of the SP2/0-Ag 14 mouse myeloma cell line.

Storage Information

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
6 months from date of despatch

More Information

Entrez Gene
GO Terms
GO:0016049 cell growth
GO:0001933 negative regulation of protein phosphorylation
GO:0002062 chondrocyte differentiation
GO:0002244 hemopoietic progenitor cell differentiation
GO:0002248 connective tissue replacement involved in inflammatory response wound healing
GO:0002576 platelet degranulation
GO:0005114 type II transforming growth factor beta receptor binding
GO:0005578 proteinaceous extracellular matrix
GO:0005615 extracellular space
GO:0005634 nucleus
GO:0005796 Golgi lumen
GO:0006611 protein export from nucleus
GO:0006754 ATP biosynthetic process
GO:0006917 induction of apoptosis
GO:0007050 cell cycle arrest
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007183 SMAD protein complex assembly
GO:0007184 SMAD protein import into nucleus
GO:0007435 salivary gland morphogenesis
GO:0048535 lymph node development
GO:0008083 growth factor activity
GO:0008156 negative regulation of DNA replication
GO:0010718 positive regulation of epithelial to mesenchymal transition
GO:0010742 macrophage derived foam cell differentiation
GO:0010763 positive regulation of fibroblast migration
GO:0010800 positive regulation of peptidyl-threonine phosphorylation
GO:0010862 positive regulation of pathway-restricted SMAD protein phosphorylation
GO:0016202 regulation of striated muscle tissue development
GO:0016563 transcription activator activity
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0019049 evasion of host defenses by virus
GO:0019058 viral infectious cycle
GO:0022408 negative regulation of cell-cell adhesion
GO:0030168 platelet activation
GO:0030308 negative regulation of cell growth
GO:0030501 positive regulation of bone mineralization
GO:0031093 platelet alpha granule lumen
GO:0031575 mitotic cell cycle G1/S transition checkpoint
GO:0032355 response to estradiol stimulus
GO:0032570 response to progesterone stimulus
GO:0032740 positive regulation of interleukin-17 production
GO:0032801 receptor catabolic process
GO:0032967 positive regulation of collagen biosynthetic process
GO:0033138 positive regulation of peptidyl-serine phosphorylation
GO:0035307 positive regulation of protein dephosphorylation
GO:0043406 positive regulation of MAP kinase activity
GO:0043536 positive regulation of blood vessel endothelial cell migration
GO:0043537 negative regulation of blood vessel endothelial cell migration
GO:0043552 positive regulation of phosphatidylinositol 3-kinase activity
GO:0043932 ossification involved in bone remodeling
GO:0045216 cell-cell junction organization
GO:0045599 negative regulation of fat cell differentiation
GO:0045930 negative regulation of mitotic cell cycle
GO:0046732 active induction of host immune response by virus
GO:0048298 positive regulation of isotype switching to IgA isotypes
GO:0050680 negative regulation of epithelial cell proliferation
GO:0050714 positive regulation of protein secretion
GO:0050921 positive regulation of chemotaxis
GO:0051781 positive regulation of cell division
GO:0051897 positive regulation of protein kinase B signaling cascade
GO:0060389 pathway-restricted SMAD protein phosphorylation
GO:0060391 positive regulation of SMAD protein import into nucleus
GO:0070723 response to cholesterol
For research purposes only

Applications of TGF Beta antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry 1
Immunohistology - Frozen
Immunohistology - Paraffin 2
Western Blotting
  1. 1 Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
  2. 2 Mouse anti Human TGF β antibody, clone TB21 has been used successfully on FFPE tissues without pretreatment e.g. Bob et al. and Booth et al.. Others have used either citrate pH6.0, EDTA pH8.0 or pepsin mediated antigen retrieval.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 1x106 cells in 100ul
Histology Positive Control Tissue
Human Breast Carcinoma

Secondary Antibodies Available

Description Product Code Applications Pack Size List Price Quantity
Goat anti Mouse IgG (H/L):Alk. Phos. (Multi Species Adsorbed) STAR117A E WB 0.5 mg loader
Goat anti Mouse IgG (H/L):DyLight®488 (Multi Species Adsorbed) STAR117D488GA F IF 0.1 mg loader
Goat anti Mouse IgG (H/L):DyLight®550 (Multi Species Adsorbed) STAR117D550 F IF WB 0.1 mg loader
Goat anti Mouse IgG (H/L):DyLight®650 (Multi Species Adsorbed) STAR117D650 F IF 0.1 mg loader
Goat anti Mouse IgG (H/L):DyLight®680 (Multi Species Adsorbed) STAR117D680GA F WB 0.1 mg loader
Goat anti Mouse IgG (H/L):DyLight®800 (Multi Species Adsorbed) STAR117D800GA F IF WB 0.1 mg loader
Goat anti Mouse IgG (H/L):FITC (Multi Species Adsorbed) STAR117F F 0.5 mg loader
Goat anti Mouse IgG (H/L):HRP (Multi Species Adsorbed) STAR117P C E WB 0.5 mg loader
Goat anti Mouse IgG (Fc):FITC STAR120F C F 1 mg loader
Goat anti Mouse IgG (Fc):HRP STAR120P E WB 1 mg loader
Rabbit F(ab')2 anti Mouse IgG:RPE STAR12A F 1 ml loader
Rabbit F(ab')2 anti Mouse IgG:HRP (Human Adsorbed) STAR13B C E P RE WB 1 mg loader
Goat anti Mouse IgG:FITC (Rat Adsorbed) STAR70 F 0.5 mg loader
Goat anti Mouse IgG:RPE (Rat Adsorbed) STAR76 F 1 ml loader
Goat anti Mouse IgG:HRP (Rat Adsorbed) STAR77 C E P 0.5 mg loader
Goat anti Mouse IgG/A/M:Alk. Phos. STAR87A C E WB 1 mg loader
Goat anti Mouse IgG/A/M:HRP (Human Adsorbed) STAR87P E 1 mg loader
Rabbit F(ab')2 anti Mouse IgG:Dylight®800 STAR8D800GA F IF WB 0.1 mg loader
Rabbit F(ab')2 anti Mouse IgG:FITC STAR9B F 1 mg loader

Negative Isotype Controls Available

Description Product Code Applications Pack Size List Price Quantity
Mouse IgG1 Negative Control MCA928 F 100 Tests loader

Application Based External Images



Immunohistology - Paraffin

Western Blotting

Product Specific References

References for TGF Beta antibody

  1. Bob, F. et al. (2014) Immunohistochemical study of tubular epithelial cells and vascular endothelial cells in glomerulonephritis.
    Ren Fail. 36: 1208-14.
  2. Lehr, al. (2010) Decellularization reduces immunogenicity of sheep pulmonary artery vascular patches.
    J Thorac Cardiovasc Surg. 141: 1056-62.
  3. Westermann, D. et al. (2011) Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction.
    Circ Heart Fail. 4: 44-52.
  4. Brown, H. et al. (1999) Cytokine expression in the brain in human cerebral malaria.
    J Infect Dis. 180: 1742-6.
  5. Helske, S. et al. (2006) Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves.
    Eur Heart J. 27: 1495-504.
  6. Hsiao, Y.W. et al. (2004) Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity.
    J Immunol. 172: 1508-14.
  7. Kingston, P.A. et al. (2003) Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty.
    Circulation. 108: 2819-25.
  8. Lavaud, S. et al. (2001) Inflammation is probably not a prerequisite for renal interstitial fibrosis in normoglycemic obese rats.
    Am J Physiol Renal Physiol. 280: F683-94.
  9. Sheu, B.C. et al. (2001) Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer.
    J Immunol. 167: 2972-8.
  10. Hopkinson, A. et al. (2006) Amniotic membrane for ocular surface reconstruction: donor variations and the effect of handling on TGF-beta content.
    Invest Ophthalmol Vis Sci. 47: 4316-22.
  11. Sumpter, T.L. et al. (2007) Regulation of the NFAT pathway discriminates CD4+CD25+ regulatory T cells from CD4+CD25- helper T cells.
    J Leukoc Biol. 83: 708-17.
  12. Braun, N. et al. (2011) Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum--implications for therapeutic targets to prevent encapsulating peritoneal sclerosis.
    Perit Dial Int. 31: 291-300.
  13. Shi, W.K. et al. (1993) [Biological characterization of a monoclonal antibody TB 21 against human transforming growth factor-beta 1].
    Shi Yan Sheng Wu Xue Bao. 26: 141-50.
  14. Bob, F.R. et al. (2011) Histological changes and immunohistochemical markers in the assessment of glomerulosclerosis in patients with glomerulonephritis.
    Rom J Morphol Embryol. 52: 1027-32.
  15. Lyras, D.N. et al. (2010) Temporal and spatial expression of TGF-beta1 in an Achilles tendon section model after application of platelet-rich plasma.
    Foot Ankle Surg. 16: 137-41.
  16. Fernandez, T. et al. (2002) Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism.
    J Exp Med. 195: 1247-55.
  17. Omer, F.M. and Riley, E.M. (1998) Transforming growth factor beta production is inversely correlated with severity of murine malaria infection.
    J Exp Med. 188: 39-48.
  18. Calveley, V.L. et al. (2010) Genistein can mitigate the effect of radiation on rat lung tissue.
    Radiat Res. 173: 602-11.
  19. Paalangara, R. et al. (2003) Intestinal exposure to a parasite antigen in utero depresses cellular and cytokine responses of the mucosal immune system.
    Vet Immunol Immunopathol. 93: 91-105.
  20. Mahmood, J. et al. (2011) Mitigation of lung injury after accidental exposure to radiation.
    Radiat Res. 176: 770-80.
  21. Ueda, S. et al. (2003) Transforming growth factor-beta1 released from the spleen exerts a growth inhibitory effect on liver regeneration in rats.
    Lab Invest. 83: 1595-603.
  22. Moussay, E. et al. (2006) Escherichia coli Shiga toxin 1 enhances il-4 transcripts in bovine ileal intraepithelial lymphocytes.
    Vet Immunol Immunopathol. 113: 367-82.
  23. Nicotina, P.A. et al. (1997) Segmental up-regulation of transforming growth factor-beta in the pathogenesis of primary megaureter. An immunocytochemical study.
    Br J Urol. 80: 946-9.
  24. Hu, H-Y. et al. (2016) ATRA alleviated endometrial fibrosis in a rabbit intrauterine adhesions model through downregulation of the TGF-β1/smad4 signaling pathway.
    Int J Clin Exp Pathol 9(6): 6171-8.
  25. Yusup, A. et al. (2015) Bone marrow lesions, subchondral bone cysts and subchondral bone attrition are associated with histological synovitis in patients with end-stage knee osteoarthritis: a cross-sectional study.
    Osteoarthritis Cartilage. 23 (11): 1858-64.
  26. Elkabir, M.A. et al. (2016) Efficacy of azithromycin and metronidazole combined therapy on rats' gingival overgrowth induced by cyclosporine-A: An experimental animal study.
    J Oral Biol Craniofac Res. 6 (3): 219-226.
  27. Attia, G.M. et al. (2017) Autologous platelet rich plasma enhances satellite cells expression of MyoD and exerts angiogenic and antifibrotic effects in experimental rat model of traumatic skeletal muscle injury
    Egypt J Histol 40 (4): 443-58
  28. Kim, M. et al. (2013) Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer.
    PLoS One. 8 (1): e53630.
  29. Gomaa, W.M. et al. (2014) Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients.
    Saudi J Gastroenterol. 20 (1): 59-65.

Fluorescent Spectraviewer

Watch the Tool Tutorial Video ▸

How to Use the Spectraviewer

Watch the Tool Tutorial Video ▸
  • Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
  • Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
  • Select the lasers and filters you wish to include
  • Select combined or multi-laser view to visualize the spectra